Cart
sales@molnova.com
Foslinanib
CAS No. 1256037-60-1
Foslinanib( TRX-818 | TRX818 )
Catalog No. M11045 CAS No. 1256037-60-1
Foslinanib (TRX-818) is an orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry (VM) activities.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 873 | Get Quote |
|
| 50MG | 1782 | Get Quote |
|
| 100MG | 2250 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameFoslinanib
-
NoteResearch use only, not for human use.
-
Brief DescriptionFoslinanib (TRX-818) is an orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry (VM) activities.
-
DescriptionFoslinanib (TRX-818) is an orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry (VM) activities, induces cancer cell apoptosis and inhibits cancer cell proliferation; also prevents tumor cell VM by blocking the formation of vasculogenic-like tubular structures through an as of yet undetermined mechanism of action.Liver Cancer Phase 2 Clinical
-
In Vitro——
-
In Vivo——
-
SynonymsTRX-818 | TRX818
-
PathwayOthers
-
TargetOther Targets
-
RecptorOther Targets
-
Research AreaCancer
-
IndicationLiver Cancer
Chemical Information
-
CAS Number1256037-60-1
-
Formula Weight365.253
-
Molecular FormulaC16H13FNO6P
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=P(O)(OC1=C(OC)C=CC(NC(C2=CC=CC(F)=C2)=C3)=C1C3=O)O
-
Chemical Name2-(3-fluorophenyl)-6-methoxy-4-oxo-1,4-dihydroquinolin5-yl dihydrogen phosphate
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
O-PHOSPHO-L-SERINE
DL-O-Phosphoserine a normal metabolite in human biofluid is an ester of serine and phosphoric acid. Serine is one of three amino acid residues that are commonly phosphorylated by kinases during cell signaling in eukaryotes.
-
Cinaciguat
Cinaciguat (BAY 58-2667) is the first of a new class of soluble guanylate cyclase (sGC) activators in clinical development for acute decompensated heart failure.
-
HS271
HS271 is a highly potent, orally active and selective IRAK4 inhibitor, with an IC50 of 7.2 μM. HS271 exhibits superior enzymatic and cellular activities, as well as excellent pharmacokinetic properties.
